Ⅱ-Ⅲ期直肠癌术后同步放化疗与术后单纯放疗临床疗效对比研究  

作　　者：奚丹[1] 裴红蕾[1] 黄瑾[1] 顾文栋[1] 宁忠华[1] 李齐林[1] 

机构地区：[1]苏州大学附属第三医院常州市第一人民医院放疗科,常州213003

出　　处：《世界中医药》2016年第B03期945-946,共2页World Chinese Medicine

摘　　要：目的回顾性分析Ⅱ-Ⅲ期直肠癌患者术后联合希罗达同步放化疗的疗效。方法：将我科收治的Ⅱ-Ⅲ期直肠癌根治术后患者，术后序贯化疗2—3周期后接受放疗。按辅助治疗方式分为2组：术后同步放化疗组和术后单纯放疗组。结果：术后同步放化疗组5年生存率分别为67．4％，高于单纯术后放疗组31．5％。Cox多因素分析显示T分期、N分期和治疗方式是影响直肠腺癌术后无病生存和总生存的独立预后因素。三级以上副反应2组对比无统计学差异。结论：术后联合希罗达同步放化能改善Ⅱ-Ⅲ期直肠癌术后生存,副反应可接受。Objective A retrospective analysis of Ⅱ-Ⅲ stage colorectal cancer patients were combined with concurrentradiotherapy and chemotherapy of Xeloda. Methods： admitted to our departmentⅡ-Ⅲ stage colorectal cancer patients afterradical resection and postoperative sequential chemotherapy 2-3 cycles after radiotherapy. Press adjuvant therapy divided intotwo groups： Postoperative concurrent radiotherapy and chemotherapy and postoperative radiotherapy group. Results：Postoperative concurrent chemoradiotherapy group, 5-year survival rates were 67.4%, higher than 31.5% postoperativeradiotherapy group. Cox multivariate analysis showed that T stage, N stage and treatment modality were independentprognostic factors for rectal cancer patients without the disease-free survival and overall survival. Three or more side effects ofthe two groups no significant difference in contrast. Conclusions： Postoperative ehemoradiotherapy can improve synchronizationXeloda Ⅱ-Ⅲ stage coloreetal cancer survival, side effects are acceptable.

关 键 词：直肠癌 三维适形放疗 希罗达 临床疗效 

分 类 号：R735.37[医药卫生—肿瘤]